CR20250095A - Células inmunitarias que coexpresan arnhc de tgfbr - Google Patents

Células inmunitarias que coexpresan arnhc de tgfbr

Info

Publication number
CR20250095A
CR20250095A CR20250095A CR20250095A CR20250095A CR 20250095 A CR20250095 A CR 20250095A CR 20250095 A CR20250095 A CR 20250095A CR 20250095 A CR20250095 A CR 20250095A CR 20250095 A CR20250095 A CR 20250095A
Authority
CR
Costa Rica
Prior art keywords
tgfbr
shrnas
expressed
immune cells
cells
Prior art date
Application number
CR20250095A
Other languages
English (en)
Inventor
Amy-Jo Casbon
Jason Hall
Brenal Singh
Adam Litterman
Natalie Bezman
Levi Gray-Rupp
John Gagnon
Aaron Cooper
Original Assignee
Arsenal Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arsenal Biosciences Inc filed Critical Arsenal Biosciences Inc
Publication of CR20250095A publication Critical patent/CR20250095A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan ácidos nucleicos recombinantes que reducen la expresión de TGFBR1 y/o TGFBR2 y células que comprenden dichos ácidos nucleicos recombinantes. También se proporcionan métodos para fabricar y utilizar dichas células
CR20250095A 2022-09-13 2023-09-13 Células inmunitarias que coexpresan arnhc de tgfbr CR20250095A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263375519P 2022-09-13 2022-09-13
US202363489840P 2023-03-13 2023-03-13
US202363495867P 2023-04-13 2023-04-13
US202363516484P 2023-07-28 2023-07-28
PCT/US2023/074047 WO2024059618A2 (en) 2022-09-13 2023-09-13 Immune cells having co-expressed tgfbr shrnas

Publications (1)

Publication Number Publication Date
CR20250095A true CR20250095A (es) 2025-09-01

Family

ID=88412303

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250095A CR20250095A (es) 2022-09-13 2023-09-13 Células inmunitarias que coexpresan arnhc de tgfbr

Country Status (16)

Country Link
US (1) US20250215438A1 (es)
EP (1) EP4587571A2 (es)
JP (1) JP2025530328A (es)
KR (1) KR20250068649A (es)
CN (1) CN120112638A (es)
AU (1) AU2023343318A1 (es)
CA (1) CA3265658A1 (es)
CL (1) CL2025000742A1 (es)
CO (1) CO2025003741A2 (es)
CR (1) CR20250095A (es)
DO (1) DOP2025000049A (es)
IL (1) IL319487A (es)
MX (1) MX2025002952A (es)
PE (1) PE20251319A1 (es)
TW (1) TW202417626A (es)
WO (1) WO2024059618A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
US20250297255A1 (en) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Systems targeting tmprss4 and slc34a2

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6773669B1 (en) 1995-03-10 2004-08-10 Maxcyte, Inc. Flow electroporation chamber and method
US6090617A (en) 1996-12-05 2000-07-18 Entremed, Inc. Flow electroporation chamber with electrodes having a crystalline metal nitride coating
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
US7029916B2 (en) 2001-02-21 2006-04-18 Maxcyte, Inc. Apparatus and method for flow electroporation of biological samples
CN1302115C (zh) 2001-04-23 2007-02-28 埃麦克萨有限公司 电穿孔用缓冲溶液及上述溶液的使用方法
AU2002326717A1 (en) 2001-08-22 2003-03-10 Maxcyte, Inc. Apparatus and method for electroporation of biological samples
AU2002343792A1 (en) 2001-11-28 2003-06-10 Center For Advanced Science And Technology Incubation, Ltd. siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME
WO2004030634A2 (en) 2002-10-02 2004-04-15 Alnylam Pharmaceuticals Inc. Therapeutic compositions
DE502004009820D1 (de) 2004-03-15 2009-09-10 Lonza Cologne Ag Behältnis und Vorrichtung zur Erzeugung von elektrischen Feldern in einzelnen Reaktionsräumen
US7771984B2 (en) 2004-05-12 2010-08-10 Maxcyte, Inc. Methods and devices related to a regulated flow electroporation chamber
JP4519915B2 (ja) 2004-06-12 2010-08-04 インビトロゲン シンガポール ピーティーイー．リミテッド． 中空構造を有する電気穿孔装置
ES2465467T3 (es) 2004-06-14 2014-06-05 Lonza Cologne Ag Procedimiento y disposición de circuito para el tratamiento de material biológico
US7991559B2 (en) 2004-11-30 2011-08-02 Maxcyte Inc. Computerized electroporation
EP1824872B1 (en) 2004-12-14 2012-02-08 Alnylam Pharmaceuticals Inc. Rnai modulation of mll-af4 and uses thereof
US8252526B2 (en) 2006-11-09 2012-08-28 Gradalis, Inc. ShRNA molecules and methods of use thereof
WO2008109546A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof
US8450112B2 (en) 2008-04-09 2013-05-28 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
US20120088842A1 (en) 2008-07-18 2012-04-12 Maxcyte, Inc. Methods for optimizing electroporation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20180127786A1 (en) 2016-09-23 2018-05-10 Casebia Therapeutics Limited Liability Partnership Compositions and methods for gene editing
WO2018232356A1 (en) 2017-06-15 2018-12-20 The Regents Of The University Of California Targeted non-viral dna insertions
JP7101419B2 (ja) 2017-10-27 2022-07-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 内因性ｔ細胞受容体の標的置換
CN112041433A (zh) * 2018-03-15 2020-12-04 Ksq治疗公司 用于改进的免疫疗法的基因调控组合物和方法
US20210207174A1 (en) 2018-05-25 2021-07-08 The Regents Of The University Of California Genetic engineering of endogenous proteins
WO2020014235A1 (en) 2018-07-09 2020-01-16 The Regents Of The University Of California Gene targets for t-cell-based immunotherapy
US12359179B2 (en) 2018-12-12 2025-07-15 The Regents Of The University Of California Compositions and methods for modifying a target nucleic acid
AU2019406186A1 (en) 2018-12-20 2021-07-15 Praxis Precision Medicines, Inc. Compositions and methods for the treatment of KCNT1 related disorders
CN113840920A (zh) 2019-03-14 2021-12-24 加利福尼亚大学董事会 合并的敲入筛选和在内源基因座控制下共表达的异源多肽
KR102691932B1 (ko) * 2019-04-03 2024-08-06 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
WO2021009701A1 (en) * 2019-07-17 2021-01-21 Curocell Inc. Enhanced immune cells using dual shrna and composition including the same
AU2020388690A1 (en) * 2019-11-20 2022-06-09 Cartherics Pty. Ltd. Method for providing immune cells with enhanced function
US20220235380A1 (en) * 2021-01-26 2022-07-28 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
CA3207166A1 (en) * 2021-02-01 2022-08-04 Angelo Leone Lombardo Gene silencing

Also Published As

Publication number Publication date
PE20251319A1 (es) 2025-05-16
IL319487A (en) 2025-05-01
JP2025530328A (ja) 2025-09-11
CN120112638A (zh) 2025-06-06
CO2025003741A2 (es) 2025-06-06
WO2024059618A2 (en) 2024-03-21
WO2024059618A3 (en) 2024-04-25
KR20250068649A (ko) 2025-05-16
CA3265658A1 (en) 2024-03-21
EP4587571A2 (en) 2025-07-23
MX2025002952A (es) 2025-06-02
CL2025000742A1 (es) 2025-07-18
AU2023343318A1 (en) 2025-04-10
TW202417626A (zh) 2024-05-01
US20250215438A1 (en) 2025-07-03
DOP2025000049A (es) 2025-06-15

Similar Documents

Publication Publication Date Title
MX2025002952A (es) Celulas inmunitarias que coexpresan arnhc de tgfbr
WO2022036126A3 (en) RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION
WO2022109398A9 (en) Oligonucleotides for dgat2 modulation
WO2021247885A3 (en) Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof
PH12022551636A1 (en) Anti-cd73 antibodies and uses thereof
MX2023005203A (es) Nanoparticulas lipidicas para administrar vacunas de arnm.
EA202191629A1 (ru) Конструкции для rnai, предназначенные для подавления экспрессии pnpla3
MX2025005078A (es) Composiciones que contienen enzimas que escinden anticuerpos y metodos de uso de las mismas.
MX2021009138A (es) Anticuerpos anti-cd228 y conjugados de anticuerpo-farmaco.
IN2014CN04131A (es)
WO2022132596A3 (en) Tissue-specific antigens for cancer immunotherapy
EA202193296A1 (ru) Конструкции для rnai, предназначенные для подавления экспрессии scap, и способы их применения
MX2023001143A (es) Anticuerpos anti-cd228 y conjugados de anticuerpos-farmacos.
MX2024015610A (es) Variantes il-12, anticuerpos anti-pd1, proteinas de fusion y usos de estos
MX2022008485A (es) Un metodo para modificar celulas asesinas naturales para dirigirse a tumores positivos a cd70.
ZA202203208B (en) Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CO2023000618A2 (es) Formulaciones no porcinas y métodos de estas
MX2024014450A (es) Composiciones de genoterapia y metodos de uso de las mismas
MX2021015667A (es) Metodo de reconstitucion de anamicina liposomica.
WO2023159136A3 (en) Epitope engineering of cell-surface receptors
WO2022235957A3 (en) Multitargeting rna immunotherapy compositions
MX2025005122A (es) Celulas geneticamente modificadas
WO2024077118A3 (en) Multispecific proteins and related methods
MX2024004913A (es) Constructos de arni para inhibir la expresion de gpam y metodos de uso de los mismos.
WO2022035739A3 (en) Compositions and methods related to ebola virusvaccines